Business Daily Media

The Times Real Estate

.

EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment

  • Written by PR Newswire
EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment

ADELAIDE, South Australia, Sept. 24, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with drug developer EnGeneIC Pty Ltd., for a project including technology transfer, process scale-up and GMP batch manufacture of EnGeneIC's proprietary 'EnGeneIC Dream Vector' (EDV) nanocells.

EnGeneIC's mission is to transform cancer treatment through targeted cyto-immunotherapy by developing Antibody-Nanocell Drug Conjugates (ANDCs) using its EDV platform, which employs antibody-targeted, non-living 'nanocells' to deliver cytotoxic payloads directly into tumor cells. ANDCs enable the use of highly potent chemotherapeutic drugs encapsulated by nanocells, thereby reducing systemic toxicity, while also offering a new means for treating drug-resistant cancers and stimulating a potent anti-cancer immune response. This dual approach aims at safer, more targeted treatments with fewer side effects, for patients with nowhere else to turn. BioCina will deliver an end-to-end package of services in preparation for clinical and commercial manufacture of EDVs.

BioCina's Chief Executive Officer, Mark W. Womack stated, "I'm so very proud for BioCina to be entrusted to advance EnGeneIC's transformative therapeutic, which has the potential to make a profound impact on previously untreatable cancers."

EnGeneIC's Co-Founder and CEO, Dr. Himanshu Brahmbhatt stated, "For several years, EnGeneIC has been searching for a contract cGMP manufacturer for its EDV cancer therapeutics. It has been a difficult road so we couldn't be more pleased to be able to entrust our technology to the professional team at BioCina. Mark Womack and his colleagues are remarkable in that they are genuinely concerned about the plight of cancer patients. This gives great confidence to EnGeneIC that the partnership will succeed in getting cGMP quality EDV therapeutics to cancer patients in a timely manner."

About BioCina

BioCina[1] is a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), offering highest-quality, cost-effective cell line, process, analytical and formulation development, and cGMP clinical & commercial manufacturing for the microbial, pDNA and mRNA modalities. BioCina's first facility in Adelaide, South Australia has a rich history of developing and manufacturing both clinical and commercial drug substance, backed by most critical SME's having an average tenure of 15+ years at the site. BioCina boasts an elite quality record having successfully passed regulatory inspections by the US FDA, EMA, TGA and Health Canada. Through a partnership with NovaCina, BioCina offers clients a highest-quality fill-and-finish solution. BioCina is proud to have clients globally, including the U.S., Europe, and the Asia Pacific. Australia offers one of the most attractive tax incentives available globally (up to 48.5% cash refund), and one of the world's premier trial networks, making it an ideal destination for biologics companies looking to invest in scaling-up and manufacturing products. Learn more at https://biocina.com[2].

About EnGeneIC

EnGeneIC is a clinical-stage biopharmaceutical company focused on advancing its proprietary EDV (EnGeneIC Dream Vector) nanocell technology for oncology and infectious disease applications. The EDV nanocell is the foundation of a first-in-class antibody nanocell drug conjugate platform for delivering a range of therapeutic payloads – drugs, siRNAs, miRNAs, adjuvants – via antibody-targeting a cancer cell's surface, with minimal toxicity. For cancer applications, the EDV technology enables delivery of the most potent chemotherapeutic agents, effectively overcoming drug-resistance and killing tumor cells, while simultaneously stimulating the patient's immune system, allowing a potent anti-tumor response. EnGeneIC is now entering Phase IIa clinical trials in Australia and the USA in patients with intractable, low survival cancers, including patients with metastatic pancreatic cancer.

Media Contactmedia@biocina.com[3]

References

  1. ^ BioCina (c212.net)
  2. ^ https://biocina.com (c212.net)
  3. ^ media@biocina.com (www.prnasia.com)

Read more https://www.prnasia.com/story/archive/4513389_AE13389_0

Empowering small businesses: Localsearch rolls out affordable digital solutions

New suite of digital solutions designed to boost visibility, engagement, and customer acquisition In response to a rapidly evolving digital lan...

Why Responsible Leadership is a Competitive Advantage for Small Businesses

In today’s fast-changing business landscape, leadership is evolving. While large corporations are reassessing their diversity, equity, and inclusi...

Why it’s a great time to include the EU in your export push

With the US market beset with unknowns, training your sights on mainland Europe in 2025 makes sound sense. Wondering whether the introduction o...

Success Isn’t About Labels—It’s About Mindset

In the lead up to International Women’s Day, I’ve been reflecting on my own success as a business owner and whether or not being a woman has playe...

Accelerate Action- Thryv champions women in business for International Women’s Day

Thryv® (NASDAQ: THRY), provider of the leading small business software platform, is celebrating International Women’s Day by shining a spotlight o...

Sydney Startup Launches AI Platform To Lead the Charge on Gender Pay Gap Action

EvenBetter.ai launches in Australia with First Customers Knight Frank and Fuji Australia Sydney-based startup EvenBetter.ai has today launched th...

Sell by LayBy